Targeting cellular membranes to heal obstructive pulmonary diseases and the metabolic syndrome

About Us

ConicMeds is a biopharmaceutical company developing a family of innovative drug candidates (NanospacersTM) for the treatment of pathologies associated with cellular lipointoxication. The unique mode of action of NanospacersTM provides new therapeutic solutions to meet major public health challenges for which medical needs are not yet fully satisfied, as evidenced by the very high progression of respiratory and metabolic diseases throughout the world.

Research and Development

Lipointoxications are characterized by an accumulation of saturated fatty acids within the membranes of the cells of our body, which affects their proper functioning. These diseases include obstructive respiratory diseases, such as Cystic Fibrosis and Chronic Obstructive Pulmonary Diseases (COPD), but also metabolic syndromes, responsible for Type 2 Diabetes, Hepatic Steatosis and certain cardiovascular diseases.

Confocal microscopy image of bronchial epithelial cells in the presence of a selective probe, which emission wavelength varies according to the membrane properties. A green color is characteristic of a weakly organized membrane (fluid) and a blue color of an ordered (rigid) membrane. As shown, lipointoxication in bronchial epithelial cells induces stiffening (decrease in fluidity) of the intracellular membranes.

Our NanospacerTM technology aims to counter the deleterious effects of lipointoxication by restoring, through the use of innovative drug candidates, the membrane properties necessary for the proper functioning of the cell. Our candidates have the unique property of inserting into the membranes and of reconfering the fluidity that the cell needs.

Incubation with our drug candidate CM-CF01, results in optimal membrane fluidity in lipointoxicated bronchial epithelial cells



ConicMeds Latest Article

Jul, 13 2018

Discover the latest research from our Cooperative Laboratory with the University of Poitiers. More...

ConicMeds Nanospacer technology for the treatment of cystic fibrosis presented at the 15th ECFS basic science conference

Mar, 21 2018

The Nanospacer technology, developed by ConicMeds for the treatment of the major symptoms associated with Cystic Fibrosis, has been presented at the 15th Basic Science Conference, organized by the ECFS (European Cystic Fibrosis Society), from 21-24 March 2018 in Loutraki (Greece). More...

ConicMeds selected for Tech Tour 2018

Jan, 29 2018

ConicMeds is selected to present its activity and its developments at the "Tech Tour 2018 - France Tech Transfer Invest", which will take place in Paris on February 13th and 14th 2018. More...

ConicMeds Development strengthens its intellectual property and confirms its development strategy

Jan, 19 2018

ConicMeds has received the agreement from the US and European patent offices for the granting of its key patent, which describes and protects its first drug candidates (NanospacersTM) for the treatment of obstructive pulmonary diseases. More...

Signature of a partnership agreement between the University of Poitiers, CNRS, SATT Grand Centre and ConicMeds.

Dec, 8 2017

On December 8, ConicMeds reached a new stage in its development by signing an exclusive license with the SATT Grand-Centre for the exploitation of a portfolio of drug candidates for the treatment of certain pulmonary diseases, such as cystic fibrosis and chronic obstructive pulmonary diseases (COPD). On this occasion, ConicMeds and the University of Poitiers also announced the creation of the cooperative laboratory "LitCh (LipoToxicity and Channelopathies) - ConicMeds". Bringing together research teams from several laboratories at the University of Poitiers, this laboratory aims to develop basic research needed to optimize drug candidates and identify new fields of application. More...

Our partners

Founded in 1431, the University of Poitiers is a fully multidisciplinary university that trains every year nearly 28,000 students. Innovative and open to the world, it mobilizes more 1,300 researchers and develops internationally recognized high-level research, in the fields of engineering sciences, including aeronautics and transport, health, environment, chemistry and humanities and social. More...

SATT Grand Centre (a “Technology Transfer Company”), is a simplified joint stock company founded on May 15, 2013 with €60M of funding over 10 years, as part of the Future Investments Programme (the Programme Investissements d’Avenir or “PIA”). SATT Grand Centre operates as a key point of contact and an interface between public research and industry to ensure the valorisation of research results, throughout the four regions in which it operates: Auvergne, Centre-Val de Loire, Limousin and Poitou-Charentes. SATT Grand Centre has the task of simplifying, accelerating and facilitating technology transfers from public research to companies, regardless of their size or business sector. More...

Contact Us

Address :
1, rue George Bonnet
86000 Poitiers

E-mail :